- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00618748
Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed
July 25, 2011 updated by: Eli Lilly and Company
Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed
To assess the efficacy and safety of olanzapine in the long-term treatment for patients with bipolar I disorder, depressed.
Study Overview
Detailed Description
This is an open-label, multi-center, long-term treatment study conducted only in Japanese sites.
The subjects are patients who fulfill the diagnostic criteria for bipolar I disorder, most recent episode depressed, as defined in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) (296.50=unspecified,
296.52=moderate severity, 296.53=severe without psychotic features, 296.54=severe with psychotic features), who have completed Study HGMP (NCT#00510146) and patients who did not participate in Study HGMP who have been recruited to participate in Study HGMS.
Study Type
Interventional
Enrollment (Actual)
101
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aichi, Japan, 470-1168
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Chiba, Japan, 270-1694
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Hiroshima, Japan, 731-0501
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Iwate, Japan, 023-0801
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Kanagawa, Japan, 231-0027
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Kyoto, Japan, 616-8421
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Saitama, Japan, 332-0012
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Shiga, Japan, 525-0037
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tokyo, Japan, 170-0002
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Yamaguchi, Japan, 755-8505
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must be aged 18 to less than 75 years.
- Each patient must be reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must understand the nature of the study and have provided informed consent.
- All female patients must test negative for pregnancy.
- Females of breast-feeding potential must agree not to breastfeed an infant during the study and for 1 month following the last dose of study drug.
- Male patients who are not surgically sterilized must agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug.
- Patients must fulfill the diagnostic criteria for bipolar I disorder, most recent episode depressed, as defined in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR).
- Patients must have experienced, in the opinion of the investigator, at least one previous manic or mixed episode, as defined in the DSM-IV-TR.
- Patients must have a current Young Mania Rating Scale (YMRS) Total score =<8.
Exclusion Criteria:
- Is investigator site personnel directly affiliated with this study or their immediate families.
- Is a Lilly employee.
- Has previously completed or withdrawn from this study or any other study investigating olanzapine.
- Is pregnant or nursing.
- Has a serious, unstable illness such that death is anticipated within 1 year or intensive care unit hospitalization for the disease is anticipated within 6 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pre-Olanzapine
Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
|
5-20 mg/day, oral, daily
Other Names:
|
Experimental: Pre-Placebo
Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
|
5-20 mg/day, oral, daily
Other Names:
|
Experimental: New Olanzapine
Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.
|
5-20 mg/day, oral, daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Adverse Events Leading to Discontinuation
Time Frame: Baseline through 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
An adverse event (AE) is an untoward medical event associated with the use of the study drug or study procedure, whether or not it is considered related to the study drug or study procedure.
Results presented are the percentage of participants who experienced an adverse event that resulted in the discontinuation of the study.
|
Baseline through 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Glucose and Lipid Panel at Week 24 or Week 48 Endpoint
Time Frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
|
Change From Baseline in Weight at Week 24 or Week 48 Endpoint
Time Frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
|
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 24 or Week 48 Endpoint
Time Frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
The MADRS is a rating scale for severity of depressive mood symptoms.
The MADRS has a 10-item checklist.
Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
|
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 24 or Week 48 Endpoint
Time Frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
The YMRS is an 11-item scale that measures the severity of manic episodes.
Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe).
The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe).
The YMRS total score ranges from 0 to 60.
|
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Change From Baseline in Clinical Global Improvement- Bipolar (CGI-BP) at Week 24 or Week 48 Endpoint
Time Frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
CGI-BP is a measure of illness severity especially adapted for bipolar illness.
It allows rating of mania, depression, and overall illness.
The scores for mania, depression, and overall illness each range from 1 (normal, not ill) to 7 (very seriously ill).
|
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Percentage of Participants With Emergence of Mania at Week 24 or Week 48
Time Frame: 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Emergence of mania is defined as first occurrence of score of >=15 in the YMRS total score in the post-baseline period of Acute Phase.
The YMRS is an 11-item scale that measures the severity of manic episodes.
Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe).
The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe).
The YMRS total score ranges from 0 to 60.
|
24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Percentage of Participants With High Suicidality at Week 24 or Week 48
Time Frame: 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors.
The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question.
The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors.
Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (>=17).
|
24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Percentage of Participants With Extra-Pyramidal Symptoms (EPS) at Week 24 or Week 48
Time Frame: 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
EPS symptoms measured by DIEPSS are grouped into 4 categories: Parkinsonism, akathisia, dystonia, and dyskinesia.
Severity ranges from level 0 (none, normal) to 4 (severe).
A participant is deemed to have EPS at endpoint if they have an abnormal endpoint.
Normal baseline Parkinsonism is defined as a score not ≥3 on 1 item or ≥2 on 2 items; abnormal endpoint is a score ≥3 on 1 item or ≥2 on 2 items, or an increase of 3 on Parkinsonism total.
Normal baseline akathisia, dystonia and dyskinesia is defined as a score <2; abnormal endpoint is a score ≥2 or an increase ≥2 from that baseline score.
|
24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Change From Baseline in Hemoglobin (HbA1c) at Week 24 or Week 48 Endpoint
Time Frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
HbA1c is a test that measures the amount of glycated hemoglobin in the blood over prolonged periods of time.
|
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Change From Baseline in Prolactin at Week 24 or Week 48 Endpoint
Time Frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
|
Change From Baseline to in QTcF at Week 24 or Week 48 Endpoint
Time Frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval)
|
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4599) or 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2008
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
September 1, 2010
Study Registration Dates
First Submitted
February 8, 2008
First Submitted That Met QC Criteria
February 8, 2008
First Posted (Estimate)
February 20, 2008
Study Record Updates
Last Update Posted (Estimate)
July 27, 2011
Last Update Submitted That Met QC Criteria
July 25, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Olanzapine
Other Study ID Numbers
- 11682
- F1D-JE-HGMS (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar I Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedBipolar I DisorderUnited States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
-
Professor Saad ShakirMerck Sharp & Dohme LLCCompletedBipolar I DisorderUnited Kingdom
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompleted
-
University of Sao PauloCompleted
-
University of Sao PauloUnknown
-
Merck Sharp & Dohme LLCRecruitingBipolar I DisorderUnited States
-
Roxane LaboratoriesCompletedBipolar I DisorderUnited States
-
Eli Lilly and CompanyCompletedBipolar I DisorderUnited States
Clinical Trials on Olanzapine
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Veterans Medical Research FoundationBristol-Myers SquibbCompleted
-
Eli Lilly and CompanyCompletedSchizophreniaUnited States, Puerto Rico, Spain, Romania, Canada, France, Argentina, Brazil, Greece, Portugal, Slovakia, Taiwan
-
Eli Lilly and CompanyCompletedSchizophrenic DisordersTurkey, Finland
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoRecruiting
-
Vanderbilt UniversityEli Lilly and CompanyCompleted
-
Alkermes, Inc.CompletedSchizophrenia | Alcohol Use DisorderUnited States, Bulgaria, Poland
-
Amani Hassan Abdel-WahabCompleted
-
Centre for Addiction and Mental HealthRecruitingInsulin Resistance | Type 2 Diabetes | Menstrual Cycle | AntipsychoticsCanada
-
The Mind Research NetworkCompleted